Ensign Peak Advisors, Inc Hutchmed (China) LTD Transaction History

Ensign Peak Advisors, Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	BUY	$35.66 - $42.94 $28,527 - $34,352	800 Added 14.55%	6,300 $231,000
Q2 2021 Aug 13, 2021	BUY	$23.7 - $39.27 $7,110 - $11,781	300 Added 5.77%	5,500 $216,000
Q1 2021 May 12, 2021	BUY	$27.01 - $36.8 $105,339 - $143,520	3,900 Added 300.0%	5,200 $147,000
Q4 2020 Feb 12, 2021	BUY	$27.51 - $34.36 $35,763 - $44,668	1,300 New	1,300 $42,000

6.88M

6.2K

1.1K

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $2.5B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.